Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.

ABSTRACT:

Purpose

Trials and past observational work compared dabigatran and warfarin in patients with atrial fibrillation, but few reported estimates of absolute harm and benefit under real-world adherence patterns, particularly in older adults that may have differing benefit-harm profiles. We aimed to estimate risk differences for ischemic stroke, death, and gastrointestinal bleeding after initiating dabigatran and warfarin in older adults (a) when patients adhere to treatment and (b) under real-world adherence patterns.

Methods

In a 20% sample of nationwide Medicare claims from 2010 to 2015, we identified beneficiaries aged 66 years and older initiating warfarin and dabigatran. We followed individuals from initiation until death or October 2015 (initial treatment, IT) and separatel

SUBMITTER: Webster-Clark M 

PROVIDER: S-EPMC8356559 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature